The outlook for Pfizer (PFE) remains mixed as the drug maker gears up for a closely-followed leadership change early next year. While
Categories
Health Care
Avid Bioservices Q2 loss narrows despite lower revenues; reaffirms outlook
Avid Bioservices (CDMO) reported a narrower net loss for the second quarter of 2019, helped by a sharp decline in costs. Revenues,
Tivity Health set to redefine fitness market with Nutrisystem acquisition
The fitness industry has witnessed a lot of innovation in recent times as companies strive to cash in on the growing penchant
Marinus Pharmaceuticals (MRNS) surges on positive data from Ganaxolone trial
Shares of Marinus Pharmaceuticals (MRNS) jumped after the pharma company reported positive data from the Phase 2 ganaxolone clinical trial in women with
Gilead names Daniel O’Day as Chairman and CEO
Gilead Sciences Inc. (GILD) has named Daniel O’Day as its new Chairman and Chief Executive Officer, effective March 1, 2019. O’Day comes
Earnings Preview: Q2 results may set the tone for Avid Bioservices’ recovery
Avid Bioservices (CDMO), a contract manufacturer in the biotechnology industry, is scheduled to release its second-quarter financial results Monday after the closing
Moderna raises over $600-million through IPO, falls below IPO price
Biotech company Moderna raised above $600 million on Thursday by selling about 26 million of its common stock at $23 a share,
Magellan Health (Nasdaq: MGLN) announces fiscal 2019 earnings outlook
Fortune-500 company Magellan Health, Inc. (NASDAQ: MGLN) today announced its fiscal 2019 outlook. The healthcare giant now sees net revenue of $7.2-$7.5
Takeda Pharmaceutical, Shire get shareholders’ nod for $62-billion deal
Takeda Pharmaceutical and Shire Plc announced that their shareholders have approved the $62 billion merger transaction. Takeda said that at least 88%
Aphria stock continues to bleed for the second day in a row
Aphria Inc. (NYSE: APHA), which nosedived 23.42% to $6.05 at the end of Monday’s trading session, continued to be in red during
GSK reorganization gains steam with Tesaro buyout, sale of Asia unit
The recent spate of cancer drugs securing FDA approval indicates that research and development in the area are progressing rapidly. So, it is
Tonix Pharmaceuticals skyrockets on additional details of a Phase 3 trial
Tonix Pharmaceuticals (Nasdaq: TNXP) stock skyrocketed during Thursday’s trading session after the pharma company announced additional details of its Phase 3 trial
Bayer looks at global lay-offs and divestments post Monsanto acquisition
German drugmaker Bayer (Frankfurt:BAYGn) on Thursday announced the divestment of many businesses, about 12,000 layoffs and $3.8 billion in impairments. The Frankfurt-listed
CVS-Aetna merger promises a new dawn for healthcare sector
The healthcare sector this week witnessed the coming together of two leading players, under a merger deal that stands out for multiple
2018 was the year of healthcare IPOs. Here is why
There were quite a few blockbuster IPOs this year, mostly by tech firms, including Spotify (SPOT), Dropbox (DBX), Elastic (ESTC) and Chinese
GW Pharma Q4 results fails to impress the street
GW Pharmaceuticals plc (Nasdaq: GWPH) stock was down about 4% in the extended hours of trading after the company missed analyst estimates
Earnings preview: GW Pharmaceuticals’ cannabis-based drug to play a major role in the future
The UK-based GW Pharmaceuticals (Nasdaq: GWPH) is set to report its fourth quarter and fiscal 2018-end results for the period ending September
Medtronic stock gains on strong Q2 results, guidance
Aided by the impressive performance of its key business segments, medical device maker Medtronic (MDT) reported a 6% increase in second-quarter revenues,
Tesaro shares spike on buyout news, trading halted
Shares of Tesaro (TSRO), an oncology-focused biopharma company, skyrocketed after the news that it has been working with advisors for a possible sale.
Arena Pharmaceuticals soars on the $1.2 billion deal with United Therapeutics
Arena Pharmaceuticals (ARNA) inked a deal with United Therapeutics (UTHR) to sell and develop its Phase 3 investigational drug candidate ralinepag worldwide.
Amarin turns positive after Citi upgrade and CEO’s clarification on REDUCE-IT study
Amarin Corporation (AMRN) shares turned to green Wednesday after they were battered out in the last two days following the data presented